|
Results Presented at the Australian and New Zealand Bone and Mineral Society (ANZBMS) Annual Meeting
HOPKINTON, MA, USA | August 28, 2008 | Alseres Pharmaceuticals, Inc., (Nasdaq: ALSE), announced that data from preclinical studies of the Company's regenerative therapy candidate, ALSE-100, were presented at the Australian and New Zealand Bone and Mineral Society Annual Conference, August 28-30, 2008 in Melbourne, Australia.
The poster presentation entitled: "Rho Inhibitor (ALSE-100) effects on bone cells in vitro" highlighted the results of a study funded by Alseres and conducted by Dr. Jillian Cornish et al. at the University of Auckland. The study investigated the effects of ALSE-100 on osteoblast and osteoclast cells in culture as well as in an organ culture system. ALSE-100 stimulated differentiation and mineralization to form bone nodules in culture and also inhibited bone resorption, osteoclast development and activity. These effects indicate that ALSE-100 could be useful in promoting bone healing.
"Rho inhibitors have previously been shown in published literature to have a beneficial effect on bone cells," noted Dr. Noel Cusack, Alseres' Senior Vice President of Preclinical Development. "We believe that this study, using a range of doses of one of our Rho inhibitor variants, ALSE-100, has demonstrated that our Rho inhibitor platform may provide potentially attractive therapeutic candidates for promoting bone healing."
About Alseres Pharmaceuticals, Inc.
Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. Cethrin, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia. The Company's lead molecular imaging product candidate is Altropane which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.
SOURCE Alseres Pharmaceuticals, Inc. |
